A detailed history of Gsa Capital Partners LLP transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 26,976 shares of CABA stock, worth $73,914. This represents 0.01% of its overall portfolio holdings.

Number of Shares
26,976
Holding current value
$73,914
% of portfolio
0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$3.94 - $8.24 $106,285 - $222,282
26,976 New
26,976 $127,000
Q2 2023

Aug 14, 2023

BUY
$7.65 - $13.95 $297,730 - $542,920
38,919 New
38,919 $502,000
Q3 2021

Nov 12, 2021

SELL
$7.0 - $12.5 $236,271 - $421,912
-33,753 Closed
0 $0
Q2 2021

Aug 05, 2021

BUY
$7.2 - $11.73 $160,221 - $261,027
22,253 Added 193.5%
33,753 $290,000
Q1 2021

May 10, 2021

BUY
$10.39 - $14.53 $119,485 - $167,095
11,500 New
11,500 $128,000

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $79.5M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.